Seoul National University Hospital
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 2003-01-01
- Employees
- 501
- Market Cap
- -
- Website
- https://www.snubh.org
Clinical Trials
2.9k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2367 trials with phase data)• Click on a phase to view related trials
Drug-Drug Interaction of Rifampicin and Cyclosporine on Methotrexate Pharmacokinetics in Healthy Subjects
- Conditions
- Drug Drug Interaction (DDI)
- Interventions
- First Posted Date
- 2025-09-29
- Last Posted Date
- 2025-09-29
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT07196449
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea
Quantitative Ultrasound(DeepUSFF) vs MRI-PDFF for Liver Fat Assessment in MASLD
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver DiseaseHepatic SteatosisLiver Disease Parenchymal
- First Posted Date
- 2025-09-25
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 62
- Registration Number
- NCT07192159
- Locations
- 🇺🇸
southwoods imaging (Northeastern Ohio Radiology Research and Education Fund ), Boardman, Ohio, United States
🇰🇷Seoul National University Hospital, Seoul, Seoul, South Korea
Enhanced Radiofrequency Ablation for Recurrent HCC Post-TACE Using Twin Internally Cooled-Perfusion Electrodes
- Conditions
- Ablation Techniques, RFARecurrent HCC
- First Posted Date
- 2025-09-25
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT07192172
- Locations
- 🇰🇷
Seoul National University Hosptial, Seoul, Seoul, South Korea
Watch and Wait or Worry and Wait in Indolent Lymphoma
- Conditions
- Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)Marginal Zone Lymphoma(MZL)Follicular Lymphoma, Grade 1Follicular Lymphoma, Grade 2Waldenström Macroglobulinemia (WM)Lymphoplasmacytic Lymphoma
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-18
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT07173790
Research for the Precision Medicine in the Treatment of Inflammatory Bowel Disease
- Conditions
- Crohn Disease (CD)Ulcerative Colitis (UC)IBD (Inflammatory Bowel Disease)
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT07166588
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Seoul, South Korea
- Prev
- 1
- 2
- 3
- 4
- 5
- 434
- Next
News
Brief Anesthesia Shows No Short-Term Neurodevelopmental Risk in Infants Under 2 Years
A randomized clinical trial of 400 children under age 2 found no meaningful differences in IQ, behavior, or language development at 30 months between those receiving sevoflurane alone versus a balanced anesthesia regimen.
Seer Launches Next-Generation Proteomics Platform Enabling Unprecedented 20,000-Sample Cancer Study
Seer's new Proteograph ONE Assay and SP200 Automation Instrument can process over 1,000 samples per week, doubling throughput while reducing per-sample costs by approximately 60% compared to 2021.
Huonslab Completes Enrollment in Phase 1 Trial for Recombinant Hyaluronidase, Eyes 2025 Regulatory Filing
Huonslab has completed patient enrollment in its pivotal Phase 1 clinical trial of HLB3-002 (Hydizyme™), a recombinant human hyaluronidase, with 243 healthy volunteers across four leading South Korean medical centers.
GemVax's GV1001 Receives FDA Fast Track Designation and Korean Therapeutic Use Approval for Progressive Supranuclear Palsy
GV1001, developed by GemVax & KAEL, has received both FDA Fast Track designation and Korean Ministry of Food and Drug Safety approval for therapeutic use in progressive supranuclear palsy patients.
Hanmi Pharmaceutical Partners with MSD to Test Novel Bispecific Antibody BH3120 in Combination with KEYTRUDA
Hanmi Pharmaceutical has entered a Clinical Trial Collaboration and Supply Agreement with MSD to evaluate its novel immunotherapy BH3120 in combination with KEYTRUDA for patients with progressive or metastatic solid tumors.